27 February 2026 in Statistics in Medicine
Recent years have seen increasing popularities in therapies that combines several drugs and/or schedules, which imposes great difficulties on the design of appropriate Phase I clinical trials. The Partial Ordering Continual Reassessment Method (POCRM), among others, is a popular design that can be easily adapted to those complex settings. However, the design is introduced and evaluated in the setting of the combination of two drugs, and the combination of more than two drugs has rarely been investigated. In particular, the specification of toxicity orderings has always been an essential part of the POCRM, which becomes more difficult in high‐dimensional settings due to the combinatorially increasing nature of the number of possible orderings of combination/schedules. This article proposes a systematic approach to specify orderings based on asymptotic properties in the setting of the combination of more than two drugs. Large simulation studies show that this novel ordering specification method leads to better design performance both asymptotically and with finite sample sizes.
18 June 2026 in Pharmaceutical Statistics
Chimeric Antigen Receptor (CAR)‐T cell is an immunotherapy which revolutionised the treatment of relapsed/refractory lymphoma and leukaemia. It is shown to have a higher response rate, higher mid‐to‐long term overall survival, and lower toxicity than standard treatments. However, due to a lack of dose‐limiting toxicity (DLT) and unclear dose‐effect relationship, traditional phase I designs of clinical trials cannot lead to accurate selections of the optimal dose (OD). Beside clinical outcomes, the CAR‐T cell expansion from serial blood samples is measured at various time points. We propose a novel early phase dose‐finding design for CAR‐T cells, using both toxicity and activity endpoints to locate the OD. The number of CAR‐T cells measured in the peripheral blood is used to indicate activity, which is more sensitive than the short‐term clinical responses traditionally used. A Bi‐Exponential model is used for the repeated measures of the number of cells for each patient, and is estimated under a Bayesian framework. The model is motivated by biological concerns and is flexible enough to accommodate different shapes of the cell‐expansion curve. Three criteria for activity are considered: (1) the number of cells at specific time points, (2) the duration before all cells are eliminated, (3) the area under the cell‐expansion curve. Simulation studies show that the OD can be selected with high accuracy even under small sample sizes.
27 May 2026 in Statistics in Medicine
The increased interest in the combination of drug agents and/or schedules requires more flexible model‐based designs for Phase I clinical trials. The models often involve more design parameters, which have to be specified before starting the trial. Those are often chosen from statistical considerations, that is, need to be optimized in a simulation study. Consequently, an efficient and systematic way for parameter calibration will both improve the model performance and save computational time. The conventional “grid search” calibration approach requires large simulations, which are computationally costly. A novel “cyclic calibration” has been proposed to reduce the computation from multiplicative to additive. Furthermore, calibration processes should consider a wide range of scenarios of true toxicity probabilities to avoid bias. A method to reduce scenarios based on scenario complexity is suggested. This can reduce the computation by more than 500‐fold, while maintaining operational characteristics similar to the grid search.
31 December 2024 in Biostatistics
Summary: Phase I clinical trials are essential to bringing novel therapies from chemical development to widespread use. Traditional approaches to dose-finding in Phase I trials, such as the ‘3 + 3’ method and the continual reassessment method (CRM), provide a principled approach for escalating across dose levels. However, these methods lack the ability to incorporate uncertainty regarding the dose-toxicity ordering as found in combination drug trials. Under this setting, dose levels vary across multiple drugs simultaneously, leading to multiple possible dose-toxicity orderings. The CRM for partial ordering (POCRM) extends to these settings by allowing for multiple dose-toxicity orderings. In this work, it is shown that the POCRM is vulnerable to ‘estimation incoherency’ whereby toxicity estimates shift in an illogical way, threatening patient safety and undermining clinician trust in dose-finding models. To this end, the Bayesian model averaged POCRM (BMA-POCRM) is formalized. BMA-POCRM uses Bayesian model averaging to take into account all possible orderings simultaneously, reducing the frequency of estimation incoherencies. We derive novel theoretical guarantees on the estimation coherency of the POCRM and BMA-POCRM. The effectiveness of BMA-POCRM in drug combination settings is demonstrated through a specific instance of estimate incoherency of POCRM and simulation studies. The results highlight the improved safety, accuracy, and reduced occurrence of estimate incoherency in trials applying the BMA-POCRM relative to the POCRM model.
16 September 2024 in arXiv
Recent years have seen increased interest in combining drug agents and/or schedules. Several methods for Phase I combination-escalation trials are proposed, among which, the partial ordering continual reassessment method (POCRM) gained great attention for its simplicity and good operational characteristics. However, the one-parameter nature of the POCRM makes it restrictive in more complicated settings such as the inclusion of a control group. This paper proposes a Bayesian partial ordering logistic model (POBLRM), which combines partial ordering and the more flexible (than CRM) two-parameter logistic model. Simulation studies show that the POBLRM performs similarly as the POCRM in non-randomised settings. When patients are randomised between the experimental dose-combinations and a control, performance is drastically improved. Most designs require specifying hyper-parameters, often chosen from statistical considerations (operational prior). The conventional "grid search'' calibration approach requires large simulations, which are computationally costly. A novel "cyclic calibration" has been proposed to reduce the computation from multiplicative to additive. Furthermore, calibration processes should consider wide ranges of scenarios of true toxicity probabilities to avoid bias. A method to reduce scenarios based on scenario-complexities is suggested. This can reduce the computation by more than 500 folds while remaining operational characteristics similar to the grid search.